Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any...

ver descrição completa

Detalhes bibliográficos
Autor principal: Butler, Javed (author)
Outros Autores: Anker, Stefan D. (author), Siddiqi, Tariq Jamal (author), Coats, Andrew J. S. (author), Dorigotti, Fabio (author), Filippatos, Gerasimos (author), Friede, Tim (author), Göhring, Udo‐Michael (author), Kosiborod, Mikhail N. (author), Lund, Lars H. (author), Metra, Marco (author), Moreno Quinn, Carol (author), Piña, Ileana L. (author), Pinto, Fausto J. (author), Rossignol, Patrick (author), Szecsödy, Peter (author), Van Der Meer, Peter (author), Weir, Matthew (author), Pitt, Bertram (author)
Formato: article
Idioma:eng
Publicado em: 2022
Assuntos:
Adherence
Heart failure
Hyperkalaemia
Mineralocorticoid receptor antagonists
Patiromer
Potassium
Renin-angiotensin-aldosterone system inhibitors
Trial design
Texto completo:http://hdl.handle.net/10451/50788
País:Portugal
Oai:oai:repositorio.ul.pt:10451/50788

Texto Completo

http://hdl.handle.net/10451/50788

Registros relacionados